Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort

Pediatrics

Volumn 117, Issue 3, 2006, Pages

  Scherpbier, Henriëtte J ^a   Bekker, Vincent ^a   Van Leth, Frank ^b   Jurriaans, Suzanne ^c   Lange, Joep M A ^b,c   Kuijpers, Taco W ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b International Antiviral Therapy Evaluation Center   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adverse effects; Growth; HAART; Long term effectiveness; Nelfinavir; Pediatric HIV

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIPOATROPHY; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; TREATMENT FAILURE; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; LAMIVUDINE; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TREATMENT FAILURE;

EID: 33645028836     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-1272     Document Type: Article

References (42)

1. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis. 1999;28:1109-1118
2. Mueller BU, Nelson RP Jr, Sleasman J, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics. 1998;101:335-343
3. Kline MW, Fletcher CV, Harris AT, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), didanosine (ddI) in children with the human immunodeficiency virus. J Pediatr. 1998;132:543-546
4. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019-1024
5. Viani RM, Araneta MRG, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:725-731
6. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528
7. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163:2187-2195
8. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression during antiretroviral therapy. AIDS. 2003;17:1907-1915
9. Soh C, Oleske JM, Brady MT, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003;362:2045-2051
10. Funk MB, Linde R, Wintergeist U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS. 1999;13:1653-1658
11. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med. 1999;341:1874-1881
12. Van Rossum AM, Geelen PM, Hartwig NG, et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34:1008-1016
13. Walker AS, Doerholt K, Sharland M, Gibb DM. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004;18:1915-1924
14. van Rossum AM, Scherpbier HJ, van Lochem EG, et al. Therapeutic immune reconstitution in HIV-infected children is independent of their age and pretreatment immune status. AIDS. 2001;15:2267-2275
15. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: aidsinfo.nih.gov. Accessed November 3, 2005
16. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. HIV Med. 2002;3:215-226
17. Van Heeswijk RP, Scherpbier HJ, de Koning LA, et al. The pharmacokinetics of nelfinavir in HIV-1 infected children. Ther Drug Monit. 2002;24:487-491
18. Kuijpers TW, Vossen MT, Gent MR, et al. Frequencies of circulating cytolytic, CD45RA+CD27-, CD8+ T lymphocytes depend on infection with CMV. J Immunol. 2003;170:4342-4348
19. Resino S, Bellón JM, Resino R, et al. Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-1 infected children. Clin Infect Dis. 2004;38:1605-1612
20. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham BS, Sullivan JL. A trial of three antiretroviral regimens in HIV-1 infected children. N Engl J Med. 2004;24:2471-2479
21. Flynn PM, Rudy BJ, Douglas SD, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004;190:271-279
22. Fraaij PLA, Verweel G, van Rossum AMC, et al. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:604-608
23. Schuster T, Linde R, Wintergeist U, et al. Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily. AIDS. 2000;14:1466-1468
24. Litalien C, Faye A, Compagnucci A, et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2003;22:48-55
25. van Leth F, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to virologic failure. AIDS Research and Human Retroviruses. In press
26. Bekker V, Sherpbier HJ, Steingrover R, Lange JMA, Wolthers K, Kuijpers TW. Viral dynamics after starting HAART in HIV-1 infected children are not correlated with age. AIDS Research and Human Retroviruses. In press
27. + T-cell count. J Acquir Immune Defic Syndr. 2004;36:702-713
28. Resino S, Galán I, Pérez A, et al. HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol. 2004;137:570-577
29. De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis. 2002;186:312-320
30. Chantry CJ, Byrd RS, Englund JA, Baker CJ, McKinney RS. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J. 2003;22:1033-1038
31. Sanchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De Jose Gomez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr. 2005;164:271-276
32. de Martino M, Chiarelli F, Moriondo M, Torello M, Azzari C, Galli L. Restored antioxidant capacity parallels the immunologic and virologic improvement in children with perinatal human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Immunol. 2001;100:82-86
33. Hardin DS, Ellis KJ, Rice J, Doyle ME. Protease inhibitor therapy improves protein catabolism in prepubertal children with HIV infection. J Pediatr Endocrinol Metab. 2004;17:321-325
34. De Martin M, Tovo PA, Galli L, et al. Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS. 2001;15:1527-1534
35. Vigano A, Mora S, Brambilla P, Schneider L, et al. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS. 2003;17:1435-1441
36. Van Rossum AM, Gaakeer MI, Verweel S, et al. Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors. Pediatr Infect Dis J. 2003;22:70-76
37. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443-1451
38. Dreimane D, Nielsen K, Deveikes A, Gegrz RC. Effects of protease inhibitors combine with standard antiretroviral therapy on linear growth and weight gain in immunodeficiency virus type 1-infected children. Pediatr Infect Dis J. 2001;20:315-316
39. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics. 2002;109(2). Available at: www.pediatrics.org/cgi/content/ full/109/2/e25
40. Steiner F, Kind C, Aebi C, et al. Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors. Eur J Paediatr. 2001;160:611-616
41. Brogley S, Williams P, Sage GR, et al, for the PCTG 219C. Antiretroviral treatment I pediatric HIV infection in the United States. JAMA. 2005;293:2213-2220
42. Yogev R. Balancing the upside and downside of antiretroviral therapy in children. JAMA. 2005;293:2272-2274